TORONTO, Feb. 25, 2016 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that Health Canada has approved its application for the generic version of PrTobi®. This respiratory antibiotic is indicated for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
PrTobi® had annual sales of approximately $9.5 million in Canada, based on IMS Brogan sales data as of November 2015. PrTeva-Tobramycin Inhalation Solution is available immediately in pharmacies across Canada. Teva Canada is the sole generic supplier of this treatment in Canada.
"Cystic fibrosis is a devastating genetic disorder where nearly half of the 4,000 affected Canadians will become infected with harmful bacterial in their lungs caused by Pseudomonas aeruginosa," said Doug Sommerville, General Manager, Teva Canada Limited. "As the sole generic supplier of Tobramycin Inhalation Solution we endeavour to play an active role in supplying patients with a lower cost option to help facilitate the medical treatment of this infection."
Cystic fibrosis is a multi-system disease affecting mainly the lungs and digestive system of young Canadians. According to the Public Health Agency of Canada, 30 to 40 per cent of those with cystic fibrosis will acquire a chronic pseudomonal infection.i
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for 50 years, with nearly 200,000ii prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,300 individuals, markets more than 400iii products in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
i Public Health Agency of Canada. Pseudomonas Spp. http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/pseudomonas-spp-eng.php. Accessed February 2016.
ii IMS Compuscript TRx MAT December 2015
iii IMS CD&H MAT December 2015
SOURCE Teva Canada Limited
Image with caption: "Teva-Tobramycin is available in 60 mg/ml inhalation solution in 56 x 5 mL ampoules (CNW Group/Teva Canada Limited)". Image available at: http://photos.newswire.ca/images/download/20160225_C1380_PHOTO_EN_628100.jpg
For further information: PR Contact: Teva Pharmaceutical Industries Ltd., Denise Bradley, Sr. Vice President, Global Corporate Reputation, Teva Pharmaceuticals, p. +1.215.591.8974, email@example.com